GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » NovoCure Ltd (FRA:038) » Definitions » Forward PE Ratio

NovoCure (FRA:038) Forward PE Ratio : 0.00 (As of May. 04, 2025)


View and export this data going back to 2015. Start your Free Trial

What is NovoCure Forward PE Ratio?

NovoCure's Forward PE Ratio for today is 0.00.

NovoCure's PE Ratio without NRI for today is 0.00.

NovoCure's PE Ratio (TTM) for today is 0.00.


NovoCure Forward PE Ratio Historical Data

The historical data trend for NovoCure's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NovoCure Forward PE Ratio Chart

NovoCure Annual Data
Trend 2019-12 2020-12 2021-12
Forward PE Ratio
85.47 322.58 588.24

NovoCure Quarterly Data
2018-09 2019-06 2019-09 2019-12 2020-03 2020-06 2020-09 2020-12 2021-03 2021-09 2021-12
Forward PE Ratio 156.25 909.09 68.49 85.47 81.97 90.91 263.16 322.58 5,000.00 909.09 588.24

Competitive Comparison of NovoCure's Forward PE Ratio

For the Medical Devices subindustry, NovoCure's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NovoCure's Forward PE Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, NovoCure's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where NovoCure's Forward PE Ratio falls into.


;
;

NovoCure Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.


NovoCure  (FRA:038) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


NovoCure Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of NovoCure's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


NovoCure Business Description

Traded in Other Exchanges
Address
Grenville Street, No. 4 The Forum, Second Floor, St. Helier, JEY, JE2 4UF
NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.

NovoCure Headlines

No Headlines